Evidence map›Paper›PMID 39591638›Full record

ArticleThe American journal of tropical medicine and hygiene2025

Implementing SARS-CoV-2 Testing during a Large-Scale Sporting Event in Africa: Lessons Learned from the Africa Football Cup of Nations Tournament in Cameroon.

Boris K Tchounga, Boris Tchakounte Youngui, Emilienne Epée, Tatiana Djikeussi, Joseph Fokam, André P Goura, Loic Feuzeu, Muhamed Awulo Mbunka, Pallavi Dani, Shannon Viana and 10 more

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Boris K TchoungaElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Boris Tchakounte YounguiElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Emilienne EpéeNational Public Health Emergency Operations Coordination Centre, Ministry of Public Health, Yaoundé, Cameroon.
Tatiana DjikeussiElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Joseph FokamChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Messa, Yaoundé, Cameroon.
André P GouraElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Loic FeuzeuElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Muhamed Awulo MbunkaElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Pallavi DaniFIND, Geneva, Switzerland.
Shannon VianaElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Anne HoppeElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Yap BoumNational Public Health Emergency Operations Coordination Centre, Ministry of Public Health, Yaoundé, Cameroon.
Rhoderick MachekanoElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Laura GuayElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Anne-Cecile Zoung-Kanyi BissekFaculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
John DitekemenaElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Appolinaire TiamElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Alain G EtoundiNational Public Health Emergency Operations Coordination Centre, Ministry of Public Health, Yaoundé, Cameroon.
Patrice TchendjouElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.
Michelle M GillElizabeth Glaser Pediatric AIDS Foundation, Yaoundé, Cameroon, and Washington, District of Columbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the 33rd Africa Cup of Nations (AFCON) football tournament in Cameroon, organizers and health authorities required a negative SARS-CoV-2 test result <48 hours before entry and provided free SARS-CoV-2 testing and vaccination at stadium and fan zone entrances. We describe the outcomes and implementation of mandatory SARS-CoV-2 testing at fan zones during AFCON. All consenting fan zones attendees were administered an electronic questionnaire capturing exposure factors, COVID-19-like symptoms, and COVID-19 vaccination status, before being tested for SARS-CoV-2 using an antigen rapid diagnostic test (Ag-RDT). Participants testing positive were sampled for confirmatory real-time SARS-CoV-2 polymerase chain reaction (PCR) and sequencing for variant surveillance. The case detection rate was estimated using PCR-confirmed cases, and the challenges were summarized from staff discussions and project/study documentation. In total, 4,820 fan zone attendees (median [interquartile range] age 30 [24-38], 27.7% females) were tested for SARS-CoV-2, including 1,228 (25.5%) fully vaccinated. Of 4,820 participants, 148 (3.1%) had a positive Ag-RDT result, of whom 67 consented to PCR testing and 19 of 64 (29.7%) were confirmed PCR-positive. The case detection rate was 40.1 (95% CI: 24.2-62.7) per 10,000 attendees. The Omicron variant (B.1.1.529) was found in all 11 samples successfully sequenced. The implementation of mandatory SARS-CoV-2 Ag-RDT at fan zone entrances was challenged by high attendance volume just prior to matches, lobbying of economic stakeholders, and inconsistent quality assurance when using test kits. Despite the challenges encountered, implementing mandatory SARS-CoV-2 Ag-RDT at fan zones, was a unique opportunity for SARS-CoV-2 case identification and genomic surveillance.

Indexed as

COVID-19COVID-19 TestingSARS-CoV-2AdultCameroonCOVID-19 VaccinesFemaleHumansMaleYoung AdultCOVID-19 Vaccines

Identifiers

PMID39591638
PMCPMC11965711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.